Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis

No Thumbnail Available
File version
Author(s)
Nash, P
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2022
Size
File type(s)
Location
License
Abstract

Janus kinase inhibitors (JAKi; or Jakinibs) have become widely prescribed around the world for a variety of immune-mediated inflammatory diseases, including psoriatic arthritis. A previous noninferiority surveillance study of patients aged > 50 years with rheumatoid arthritis and ≥ 1 additional cardiac risk factor raised a number of safety concerns. This review focuses on available safety data from peer-reviewed publications, as well as the most recent presentations from major conferences highlighting JAKi-associated adverse effects. The safety data for several types of JAKi are reviewed. The latest available safety data for tofacitinib, upadacitinib, filgotinib, deucravacitinib, and brepocitinib is presented. In addition, the findings from the oral surveillance study will be discussed to put safety concerns into context.

Journal Title

The Journal of Rheumatology

Conference Title
Book Title
Edition
Volume

49

Issue

6

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Rheumatology and arthritis

Clinical pharmacology and therapeutics

GRAPPA

psoriasis

psoriatic arthritis

Persistent link to this record
Citation

Nash, P, Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis, The Journal of Rheumatology, 2022, 49 (6), pp. 44-47

Collections